Sign in
Taking people in United KingdomNo phase

Hearing loss after platinum chemotherapy in people with cancer from different backgrounds

Looks at hearing changes after platinum chemotherapy in adults with cancer.

Key facts

Who runs it
Lancaster University
Where
Lancaster, United KingdomSee the site
Trial code
Registry title
Chemotherapy-Induced Hearing Loss and Health Inequality
Status
Recruiting
People taking part
172 people, planned
Started
2 May 2026
Expected to end
1 Sept 2028
Type of study
Observational
Record updated
10 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cancer who are getting platinum-based chemotherapy, such as cisplatin, in North West England. It studies hearing loss and thinking skills.

Age
18 Years and older
Sex
All
Disease stage
Stage 4 cancer cannot join. People with a WHO performance status score of 3 or more cannot join. This score measures how well you manage daily activities.
Earlier treatment
People must be receiving platinum-based chemotherapy drugs.

Main reasons for not taking part

  • Brain tumour or cancer spread to the brain, head and neck cancer, skin cancer around the ear, or adenoid cystic carcinoma of the auditory cortex
  • Deafness in childhood, a cochlear implant, or current or recent ear infections
  • Known nerve or brain problems, such as stroke, brain injury or dementia
  • Not able to give consent or do the study tasks
  • Must live and be treated in North West England, speak English fluently, and be able to do an online hearing and thinking test

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Patients receiving platinum-based chemotherapy drugs
  • Living and treated within North West England
  • Able to complete an online hearing and cognitive test
  • Fluent in English

Who cannot take part

  • Cochlear implant user
  • Following cancer types: brain tumour/metastasis, head + neck, skin cancers around the ear, and adenoid cystic carcinoma of the auditory cortex
  • Stage 4 cancer
  • History of childhood deafness
  • Current or recent ear infections
  • Known neurological impairment (e.g., stroke, traumatic brain injury, dementia)
  • World Health Organisation performance status score of 3 or more
  • Patients who look capacity to consent or complete study tasks

Where in United Kingdom

  • Lancaster UniversityLancaster, United KingdomContact: Helen NuttallTaking people

About the trial

What the trial wants to find out

This project aims to understand how platinum-based chemotherapy affects hearing function in cancer patients from different socioeconomic backgrounds in the North West of England. Platinum-based chemotherapy drugs, such as cisplatin, are ototoxic, meaning that they cause permanent damage to the hair cells of the ear, resulting in hearing loss. Patients from more deprived backgrounds face additional risk factors to their hearing health, including limited healthcare access, greater occupational noise exposure, and poorer overall health, making them more vulnerable to hearing loss.

Read full original descriptionShow less

This is especially concerning as hearing loss can make communication more challenging, which creates a greater reliance on cognitive processes such as thinking and memory to navigate social interactions. This challenge is exacerbated when individuals experience cognitive dysfunction related to chemotherapy, commonly referred to as 'chemo brain'. Addressing these communication difficulties is crucial for promoting healthy ageing and maintaining social engagement. It is expected that cancer patients from the most deprived backgrounds would experience greater hearing loss following chemotherapy than those from less deprived backgrounds.

As a secondary aim, this study will also investigate how hearing loss may affect cognitive function. Specifically, it will assess whether differences in speech-in-noise performance from pre- to post-treatment predict cognitive performance post-treatment, to understand if changes in hearing over time are associated with changes in cognition. The study will also explore how socioeconomic deprivation, cumulative chemotherapy dose, and treatment duration influence these relationships. By identifying disparities in hearing loss and possible associations with cognition, this research will help guide future hearing screening and intervention strategies for cancer patients.

The group in the trial

  • Chemotherapy patients

    Patients set to be treated with platinum-based chemotherapy drugs in the North West of England.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Chemotherapy-Induced Hearing Loss and Health Inequality
Plain-language title
Hearing loss after platinum chemotherapy in people with cancer from different backgroundsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
10 September 2026